Netupitant-Palonosetron FDC are expected to attain an estimated value of US$ 515.0 million by 2018

The global chemotherapy-induced nausea and vomiting (CINV) market is expected to reach USD 1.7 billion by 2015, due to prevalent cancer related conditions and subsequent increase in the CINV pool. The global CINV patient pool is estimated to reach 4.6 million by 2015. The Asian region is expected to witness the largest patient share for CINV contributing majorly to the total CINV patient pool thereby presenting a huge potential for the Netupitant – Palonosetron market. This report initially starts with the thorough analysis of the CINV market, its potential, the target patient pool, with forecast period covering 2009-2015. This report also covers the basic knowledge of the Netupitant – Palonosetron FDC and its mode of action, along with an estimation of their sales projection, current scenario, SWOT analysis, clinical trials and opportunities. It also covers the factors driving this market and the regional analysis including United States, Europe, Australia and UK among others. The present market condition and performance has been mentioned in detail along with the CINV patient pool. Moreover, the report provides in-depth analysis of Netupitant – Palonosetron FDC market with their estimated and forecast market size till 2018.

This in-depth analysis of Netupitant-Palonosetron FDC market helps provide an understanding of the various driving factors for the growth of the market. The market overview section of this report analyzes the market dynamics and trends with the help of SWOT analysis, which influence the current nature and future status of this market. SWOT analysis includes strength, weakness opportunities and threats for the Netupitant-Palonosetron FDC manufacturer. Global CINV market qualitative study is also been presented in this report, this covers the impact of CINV in for Netupitant – Palonosetron FDC market. Impact factors such as market attractiveness analysis, that includes the study of target patient pool, and sales projection analysis with forecast of the sales in terms of USD for the decade 2000-2010, these sections have also been quantitatively explained in the market overview section of the report in order to deliver a thorough analysis of the overall competitive scenario of the global Netupitant – Palonosetron FDC market.

Download Complete PDF Brochure:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=729

The fixed dose combination (FDC) of netupitant and palonosetron is a product proposed for the treatment of the most common side-effects of chemotherapy – nausea and vomiting. The product is currently in its third stage of trial. Netupitant is a novel and a very selective NK1 receptor antagonist, and palonosetron is a second generation and clinically discrete 5-HT3 receptor antagonist. While netupitant has never been in the drug market before, palonosetron drugs are already available under trade names such as Paloxi, Onicit and Aloxi.

Netupitant-Palonosetron FDC is expected to provide an effective solution to many significant unmet needs of the CINV market. The combination drug is expected to overcome major problems associated with the current mode of treatment of the CINV condition, which currently involves the use of 5-HT3 receptor antagonists only.

The FDC combination of netupitant and palonosetron has revealed efficient results in Phase II clinical trials. It is being expected that the demand for this drug would observe high uptake as physician and patient preferences would shift towards better treatment methods for CINV.

The report estimates that the drug would acquire considerable patient pool after it is launched in 2014. Its market is estimated to match patient-base of the drug Aloxi by 2018. Overall sales of Netupitant-Palonosetron FDC are expected to attain an estimated value of US$ 515.0 million by 2018.

The report estimates that the target market for such a combination drug, the global chemotherapy-induced nausea and vomiting (CINV) market, is estimated to observe growth at a CAGR of 7.1%, and grow to achieve a market value worth US$ 1.7 billion by 2015. The high prevalence of many types of cancers and the subsequent rise in CINV patient pool is estimated to be the major reason behind the growth of the global CINV market.

Browse Full Research Report:
http://www.transparencymarketresearch.com/netupitant-palonosetron-fdc-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s